An immuno-diffusion assay to assess the protective antigen content of anthrax vaccine

被引：6

作者：

Adams, T ^{[1
]}

Osborn, S ^{[1
]}

Rijpkema, S ^{[1
]}

机构：

[1] Natl Inst Biol Stand & Controls, Div Bacteriol, Potters Bar EN6 3QG, Herts, England

来源：

VACCINE | 2005年 / 23卷 / 36期

关键词：

anthrax; vaccines; protective antigen;

D O I：

10.1016/j.vaccine.2005.04.017

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The UK anthrax vaccine uses the culture supernatant of toxigenic non-encapsulated Bacillus anthracis as a crude source for protective antigen (PA). The precise amount of PA is not known. We developed a single radial immuno-diffusion (SRD) assay and an indirect ELISA to measure PA in desorbed anthrax vaccines. Based on 23 batches, the PA contents varied from 19.1 to 88.8 mu g ml(-1), with an average of 39.6 mu g ml(-1). Analysis of four batches by ELISA revealed considerably lower levels of PA. This discrepancy can be explained by competition of other proteins for binding sites, which results in an artificially low amount of bound PA per well. We conclude that the SRD assay is a reproducible method for the measurement of PA and this assay will contribute to quality control and improve the specifications of current anthrax vaccines. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：4517 / 4520

页数：4

共 22 条

[1]

BELTON FC, 1954, BRIT J EXP PATHOL, V35, P144

[2] FIELD-EVALUATION OF A HUMAN ANTHRAX VACCINE [J].

BRACHMAN, PS ;

FEKETY, FR ;

GOLD, H ;

WERRIN, M ;

INGRAHAM, NR ;

PLOTKIN, SA .

AMERICAN JOURNAL OF PUBLIC HEALTH AND THE NATIONS HEALTH, 1962, 52 (04) :632-+

[3] Anthrax [J].

Dixon, TC ;

Meselson, M ;

Guillemin, J ;

Hanna, PC .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (11) :815-826

[4]

HAMBLETON P, 1984, Vaccine, V2, P125, DOI 10.1016/0264-410X(84)90003-3

[5] Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques [J].

Ivins, BE ;

Pitt, MLM ;

Fellows, PF ;

Farchaus, JW ;

Benner, GE ;

Waag, DM ;

Little, SF ;

Anderson, GW ;

Gibbs, PH ;

Friedlander, AM .

VACCINE, 1998, 16 (11-12) :1141-1148

[6] Bioterrorism-related inhalational anthrax: The first 10 cases reported in the United States [J].

Jernigan, JA ;

Stephens, DS ;

Ashford, DA ;

Omenaca, C ;

Topiel, MS ;

Galbraith, M ;

Tapper, M ;

Fisk, TL ;

Zaki, S ;

Popovic, T ;

Meyer, RF ;

Quinn, CP ;

Harper, SA ;

Fridkin, SK ;

Sejvar, JJ ;

Shepard, CW ;

McConnell, M ;

Guarner, J ;

Shieh, WJ ;

Malecki, JM ;

Gerberding, JL ;

Hughes, JM ;

Perkins, BA .

EMERGING INFECTIOUS DISEASES, 2001, 7 (06) :933-944

[7]

JOELLENBECK LM, 2002, ANTHRAX VACCINE MANU, P180

[8] Clinical presentation of inhalational anthrax following bioterrorism exposure - Report of 2 surviving patients [J].

Mayer, TA ;

Bersoff-Matcha, S ;

Murphy, C ;

Earls, J ;

Harper, S ;

Pauze, D ;

Nguyen, M ;

Rosenthal, J ;

Cerva, D ;

Druckenbrod, G ;

Hanfling, D ;

Fatteh, N ;

Napoli, A ;

Nayyar, A ;

Berman, EL .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (20) :2549-2553

[9] The roles of anthrax toxin in pathogenesis [J].

Moayeri, M ;

Leppla, SH .

CURRENT OPINION IN MICROBIOLOGY, 2004, 7 (01) :19-24

[10] In vitro correlate of immunity in a rabbit model of inhalational anthrax [J].

Pitt, MLM ;

Little, SF ;

Ivins, BE ;

Fellows, P ;

Barth, J ;

Hewetson, J ;

Gibbs, P ;

Dertzbaugh, M ;

Friedlander, AM .

VACCINE, 2001, 19 (32) :4768-4773

← 1 2 3 →